Kusajili – Centralise les essais cliniques mondiaux

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol M04-691.

• Pays Australia, Belgium, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, South Africa, Spain, Sweden, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog® To compare efficacy and safety of Exubera® vs Humalog in patients with type 1 diabetes mellitus

• Pays Austria, Belgium, Denmark, Finland, France, Ireland, Netherlands, Norway, Portugal, Spain, Sweden, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.

• Pays Australia, Belgium, Canada, France, Germany, Ireland, Italy, Netherlands, Spain, Sweden, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun

A Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Patients With Multiple Myeloma The study compared the efficacy of oral lenalidomide in combination with oral pulse high-dose dexamethasone to that of placebo and oral high-dose pulse dexamethasone as treatment for participants with relapsed or refractory multiple myeloma.

• Pays Australia, Austria, Belgium, France, Germany, Greece, Ireland, Israel, Italy, Poland, Spain, Sweden, Switzerland, Ukraine, United Kingdom,
• Organes Aucun
• Spécialités Aucun

Airflow Limitation in Cardiac Diseases in Europe This is a cross-sectional, observational study, investigating the point prevalence of Airflow Limitation in current or former smokers with established ischemic heart disease. The study will recruit up to 3000 patients from cardiology clinics at hospitals across Europe.

• Pays Belgium, France, Germany, Greece, Ireland, Italy, Netherlands, Spain, Sweden,
• Organes Aucun
• Spécialités Aucun

FMS European Long-Term Study Investigation of the long-term (12 months) efficacy and safety of milnacipran used in the treatment of fibromyalgia syndrome.

• Pays Czech Republic, Finland, France, Germany, Italy, Norway, Portugal, Romania, Spain, Sweden,
• Organes Aucun
• Spécialités Aucun

Kuvan® Adult Maternal Pediatric European Registry

• Pays Austria, France, Germany, Italy, Netherlands, Slovakia, Spain, Sweden,
• Organes Aucun
• Spécialités Aucun

A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis This study is being conducted to compare the efficacy of ABT-874 versus Methotrexate in subjects with moderate to severe plaque psoriasis.

• Pays Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom,
• Organes Aucun
• Spécialités Aucun

BI 44370 TA in Acute Migraine Attack The objective of this trial is to assess the safety, tolerability, and efficacy of three doses of BI 44370 TA in the treatment of patients with an acute migraine attack and headache pain of moderate or severe intensity, compared to placebo and an active comparator.

• Pays Belgium, El Salvador, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom,
• Organes Aucun
• Spécialités Aucun

Imatinib (QTI571) in Pulmonary Arterial Hypertension A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).

• Pays Austria, Belgium, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, Switzerland, United Kingdom, United States,
• Organes Aucun
• Spécialités Aucun